TABLE 1.

Effect of APS on adaptive immune therapy.

Cell line	Dosage	Effect of APS on adaptive immune therapy	Ref
SKov3 cell	APS 100 mg/L, 3 d	CIK cytotoxicity↑	Xu et al. (2011)
Hela cell in female BALB/c mice	APS 250,500,1000 mg/L, twice a week, 3 w	CIK cytotoxicity↑	Huo and Shan (2016)
Eca-109 cell	APS 100 mg/L, 7 d	DC-CIK cells cytotoxicity↑	Wang et al. (2016)
pDC cell	APS 50,100, 200 mg/L, 1 d	IFN-α↑, TNF-α↑, and IL-6↑ by pDC; CD11c↑, CD80↑, and CD86↑	Liu et al. (2010)
A549 cell	APS 100 mg/L, 2 d	IFN-γ↑, IL-12↑, CD40↑, CD80↑, and HLA↑ in DCs, cytotoxicity of DC-CIK cells↑	Zhang et al. (2009)
LAK cell, Hela cells	APS 1000 mg/L, 3 d	Dead and apoptotic LAK cells↓	Yang and Zhao (1998)
K562 cells	APS 100 mg/L, 2 d	IFN-γ↑, IL-12↑, CD40↑, CD80↑, and HLA↑ in DCs, cytotoxicity of DC-CIK cells↑	Chen and Zhang (2013)
Kunming mice with S180 cell tumor	APS 100 mg/L, 2 d	CD86↑, CD80↑, in DC,TNF-α↑, and IL-12↑	Qiu et al. (2015)
DCs-CIK cell; Hela cell	APS 300 mg/L, 3 d	CD3+CD8+, CD3+CD56+, TNF-α, and IFN-γ in DCs-CIK; CD14↓, CD80↑, CD83↑, CD86↑, CDllc↑, HLA-I↑, and HLA−II↑ in DCs; TNF-β↑ and IFN-γ↑	Gong and Ju (2016)
K562 cells	APS 1000 mg/L, 3 d	LAK cytotoxicity ↑	Wang et al. (1995)
BALB/c mice with S180 cell tumor after CTX treatment	200 mg/kg, 8 d	NK cells↑; IL-2↑, IL-3↑, IL-4↑, IL-6↑, and IFN-γ↑	Weng et al. (2003)
HL-60 cells	15 mg/ml, 2 d	MICA expression↑ in HL-60 cells, sensitivity of HL-60 cells↑ to NK cells	Zeng et al. (2012)
Splenic DCs	APS 50,100,200 mg/L, 1 d	CD11c (high) CD45RB (low) DCs↑, Th2 to Th1↑, T lymphocyte immune function↑	Liu et al. (2010)
Spleen of BALB/c mice	0–200 mg/L, 7 d	Macrophage cytotoxicity↑, NK cell cytotoxicity↑, IgG↑ in supernatant	Wang et al. (2008)
pDC cell from CML patients	APS 50,100, 200 mg/L, 1 d	IL-6↑, TNF-α↑ secreted by pDC in treatment-naive CML patients, IFN-α↑, IL-6↑, TNF-α↑ secreted by pDC in remission stage patients	Liu (2009)